|
Published by: Business Insights
Published: Jan. 1, 2008 - 101 Pages
Table of Contents
- Launching combination products
- Executive Summary
- An introduction to combination products
- Combination product strategies in the cardiovascular market
- Combination product strategies in the respiratory market
- Combination product strategies in the diabetes market
- Combination product strategies in the HIV market
- Combination product strategies in the women’s health market
- Combination product strategies in other therapeutic markets
- Brand extension and franchise development strategies
- Chapter 1 An introduction to combination products
- Summary
- Introduction
- Therapeutic value
- Combining therapies
- Improved convenience
- Commercial value
- Brand extension
- Franchise development
- Leading combination products
- Key products
- Key therapeutic categories
- Key combination product strategies
- Chapter 2 Strategies for cardiovascular products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Exforge
- Future combination product developments
- Simcor
- Avandia/simvastatin
- Key combination product launch strategies
- Chapter 3 Strategies for respiratory products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Symbicort
- Future combination product developments
- Singulair/Claritin
- Flutiform
- Key combination product launch strategies
- Chapter 4 Strategies for diabetes products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Janumet
- Duetact
- Future combination product developments
- Avandia/simvastatin
- Synordia
- Key combination product launch strategies
- Chapter 5 Strategies for HIV products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Atripla
- Future combination product developments
- Key combination product launch strategies
- Chapter 6 Strategies for women’s health products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Lybrel
- Angeliq
- Future combination product developments
- Aprela
- DUB-OC
- Key combination product launch strategies
- Chapter 7 Strategies for other therapeutic areas
- Summary
- Introduction
- Leading combination products
- Anti-infectives
- Recent combination product launches
- Combigan
- Ziana
- Pylera
- Future combination product developments
- Oncology
- CNS and pain
- Key combination product launch strategies
- Chapter 8 Brand extension and franchise development strategies
- Summary
- Introduction
- Case studies
- Diovan, Diovan HCT/Co-Diovan and Exforge
- Avandia, Avandamet and Avandaryl
- Advair/Seretide
- Case study: Kaletra
- Case study: Vytorin
- Key success factors
- Branding
- Pricing
- Positioning
- Chapter 9 Appendix
- Sources
- Product sales data
- Regulatory data
- Specific sources
- List of Figures
- Figure 1.1: Number of combination products by therapy area, 2006
- Figure 1.2: Key combination product strategies
- Figure 2.3: Key cardiovascular combination product strategies
- Figure 3.4: Key respiratory combination product strategies
- Figure 4.5: Key diabetes combination product strategies
- Figure 6.6: Key women’s health combination product strategies
- Figure 8.7: Diovan, Diovan HCT/Co-Diovan sales, 2002-2006
- Figure 8.8: Avandia, Avandamet and Avandaryl sales, 2002-2006
- Figure 8.9: Advair/Seretide, Flovent/Flixotide and Serevent sales, 2002-2006
- Figure 8.10: Kaletra sales, 2002-2006
- Figure 8.11: Vytorin, Zetia and Zocor sales, 2002-2006
- List of Tables
- Table 1.1: Leading brand extension combination products, 2006
- Table 1.2: Leading brand extension combination products, 2006
- Table 1.3: Leading franchise development combination products, 2006
- Table 2.4: Leading brand extension combination products in the cardiovascular market, 2004- 2006
- Table 2.5: Leading franchise development combination products in the cardiovascular market, 2004-2006
- Table 2.6: Recently approved combination products in the cardiovascular market, 2005-2007
- Table 2.7: Future combination products in development for the cardiovascular market, 2007
- Table 3.8: Leading brand extension combination products in the respiratory market, 2004-2006
- Table 3.9: Leading franchise development combination products in the respiratory market, 2004- 2006
- Table 3.10: Recently approved combination products in the respiratory market, 2005-2007
- Table 3.11: Future combination products in development for the respiratory market, 2007
- Table 4.12: Leading brand extension combination products in the diabetes market, 2004-2006
- Table 4.13: Recently approved combination products in the diabetes market, 2005-2007
- Table 4.14: Future combination products in development for the diabetes market, 2007
- Table 5.15: Leading franchise development combination products in the HIV market, 2004-
- Table 5.16: Recently approved combination products in the HIV market, 2005-2007
- Table 6.17: Leading brand extension combination products in the women’s health market, 2004- 2006
- Table 6.18: Leading franchise development combination products in the women’s health market, 2004-2006
- Table 6.19: Recently approved combination products in the women’s health market, 2005-2007
- Table 6.20: Future combination products in development for the women’s health market, 2007
- Table 7.21: Leading brand extension combination products in other therapeutic markets, 2004- 2006
- Table 7.22: Leading franchise development combination products in other therapeutic markets, 2004-2006
- Table 7.23: Recently approved combination products in other therapeutic markets, 2005-2007
- Table 7.24: Future combination products in development for other therapeutic markets, 2007
AbstractCombination pharmaceutical products, or fixed-dose combinations (FDC’s), offer benefits to many drug classes due to the additive nature of therapeutic effect and the reduced level of side-effects associated with their use. Their core advantage however is an improvement in convenience that stems from reducing prescription numbers and their associated administrative costs. Although fixed-dose combination drugs have historically attracted disapproval from physicians, who typically prefer to determine the components and ratios of drug applications at their own discretion, a widespread acknowledgement and acceptance of these therapies has now been established. This is largely due to their effectiveness in areas such as HIV and asthma, but the successful positioning of combination products remains difficult in therapeutic areas where combination therapies only provide marginally incremental benefits. Launching Combination Products is a new report published by Business Insights that provides detailed strategic guidance for the preparation and successful execution of combination product launches. This report performs a comprehensive examination of current competitive pressures, best practices and future developments in key therapeutic areas including cardiovascular, respiratory, HIV and women’s health. Detailed case studies also provide unique insights into the brand extension and franchise development strategies of leading companies and help to identify the key success factors behind recent combination product launches. Discover potential growth opportunities for your brands, identify future combination launches and use case studies to understand the most effective launch strategies across key therapeutic areas with this new report.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
